Krabbe Disease
New Krabbe disease research, summarized each month in plain language.
2026 so far: So far in 2026 (January to September), HSCT timing and disease stage stayed central. Pooled data suggested high survival, frequent GVHD (graft-versus-host disease, when donor cells attack the body), and limited reporting on longer-term function. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Stem cell transplant outcomes. Earlier transplant was linked to better outcomes, but pooled data showed big reporting gaps.
- Supportive and complex care. Case reports described seizure-focused care and unexpected medical needs.
- After a positive screen. Guidance and systems work aimed to reduce delays and confusion in follow-up.
- MRI and biomarkers. MRI descriptions became more structured, but prognosis was still hard to pin down.
- Preclinical therapy research. Cell and mouse work explored several ways to target the underlying biology.
New
September 2026
- Transplant survival. Pooled reports suggested high survival after stem cell transplant.
- Immune side effects. GVHD was often reported after stem cell transplant.
- Nerve and MRI follow-up. Long-term neurologic and MRI results were often not reported.
- Adult-onset imaging. In adult-onset cases, MRI changes could be mild or unclear.
August 2026
- Genetic diagnosis. Genetic testing confirmed Krabbe disease after symptoms were advanced.
- Seizure care. With advanced disease, care focused on seizure medicines and support.
- MRI progression. MRI changes progressed despite early development appearing preserved.
- Cord blood transplant. After transplant, one screened child had stable MRI and development.
June 2026
- Screening test alignment. Shared test samples helped labs match newborn screening results.
- Follow-up discussions. Clinicians described knowledge and time gaps during early family talks.
- Psychosine cell model. A new human cell model tracked psychosine changes in the lab.
May 2026
- Variant-specific shape changes. Different GALC variants were predicted to change the enzyme’s shape in different ways.
- Substrate pocket size. Some variants were predicted to change the size of the enzyme pocket where the substrate would normally fit.
- Stability salt bridge. Several variants were predicted to weaken an internal “salt bridge” that helps stabilize the enzyme.
April 2026
- Confirm quickly after a positive screen. Reports described a positive newborn screen as time-sensitive, with confirmatory testing needed quickly.
- Transplant timing matters. Hematopoietic stem cell transplant was described as most effective when done very early, ideally before symptoms.
- Gene correction in mice. In a Krabbe mouse model, partial correction of a GALC gene change was linked to improved brain and nerve-related measures.
- Ongoing medical needs in survivors. A single long-term survivor case report described surgery for a collapsed lung (spontaneous pneumothorax).
February 2026
- Four MRI pattern groups. In symptomatic Krabbe disease, brain MRI findings were grouped into four recurring patterns, with earlier-onset cases tending to cluster together and later-onset cases more often showing different white matter patterns.
- GALC variant reports. Reports added detail on GALC gene changes, including a newly described variant in one of two unrelated patients (the other had a known variant) and summaries of variants seen in adult-onset cases alongside wide symptom variation.
- Psychosine-binding in models. In cells and a Krabbe mouse model, a cyclodextrin compound was linked to lower psychosine and improved myelin-related measures, but this is still preclinical evidence and not a proven human therapy.
January 2026
- Transplant timing. Earlier HSCT was linked to better later function.
- Caregiver workload. Caregivers reported less daily burden after pre-symptom HSCT.
- Transplant safety. Transplant-related deaths were reported, including after early HSCT.
Get the monthly update by email
Subscribe here to receive an email when a new monthly Krabbe disease update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).